2023
12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial
Lynce F, Brasó-Maristany F, Waks A, Gonzalez P, Villacampa G, Torres E, Galván P, Brunet L, Anderson L, Perou C, Parker J, Vivancos A, Dilullo M, Simon S, Winer E, Overmoyer B, Mittendorf E, Prat A, Tolaney S. 12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial. ESMO Open 2023, 8: 101236. DOI: 10.1016/j.esmoop.2023.101236.Peer-Reviewed Original Research
2019
Aggressive Subsets of Metastatic Triple Negative Breast Cancer
Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer 2019, 20: e20-e26. PMID: 31631016, DOI: 10.1016/j.clbc.2019.06.012.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerInflammatory breast cancerTriple-negative breast cancerWorse overall survivalYounger patientsOverall survivalBreast cancerIBC groupMetastatic breast cancer subtypesYounger groupFrequent lung metastasisMedian overall survivalSite of metastasisSingle-institution cohortNegative breast cancerBreast cancer subtypesClinicopathologic characteristicsMetastatic diagnosisMetastatic sitesWorse prognosisLung metastasesPoor prognosisSurvival outcomesPrimary diagnosisAggressive subset
2018
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. Npj Breast Cancer 2018, 4: 10. PMID: 29761158, PMCID: PMC5935675, DOI: 10.1038/s41523-018-0060-z.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerTriple-negative breast cancerPhase II studyBreast cancerII studyObjective responseNon-randomized phase II studyIL-6/JAK2/STAT3Efficacy of ruxolitinibInfrequent grade 3Refractory patient populationPrimary efficacy endpointMetastatic breast cancerInflammatory breast cancerSelective JAK1/2 inhibitorArchival tumor tissueJAK2/STAT3Central immunohistochemistryCommon toxicitiesRECIST 1.1Efficacy endpointPrimary endpointProtocol therapyJAK1/2 inhibitorPatient population
2013
Phase II study of ruxolitinib in patients with pStat3+ breast cancer.
Lin N, Gelman R, Brock J, Bardia A, Mayer E, Overmoyer B, Wang V, Iannone M, Krop I, Polyak K, Winer E. Phase II study of ruxolitinib in patients with pStat3+ breast cancer. Journal Of Clinical Oncology 2013, 31: tps1134-tps1134. DOI: 10.1200/jco.2013.31.15_suppl.tps1134.Peer-Reviewed Original ResearchBreast cancerObjective responseCohort BCohort AOpen-label phase 2 trialIL-6/JAK2/STAT3Tumor tissueM.D. Anderson Symptom InventoryTriple-negative breast cancerAdequate organ functionBaseline tumor biopsiesECOG PS 0High-risk myelofibrosisPhase II studyEORTC QLQ CPhase 2 trialInflammatory breast cancerArchival tumor tissueWk 4JAK2/STAT3Further studiesAccessible diseaseMeasurable diseasePrior therapyPrimary endpoint